What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Research analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of Genmab A/S in a report issued on Wednesday, February 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.15 per share for the quarter, down from their previous estimate of $0.27. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.54 EPS and FY2026 earnings at $1.75 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion.

A number of other analysts have also recently commented on GMAB. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday. They issued a “buy” rating and a $41.50 target price for the company. Truist Financial reiterated a “buy” rating and set a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Morgan Stanley assumed coverage on Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Finally, Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.30.

Genmab A/S Price Performance

Shares of GMAB stock opened at $29.29 on Friday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 6.01 and a current ratio of 2.02. The firm has a market capitalization of $18.82 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 16.53 and a beta of 0.90. The stock’s 50-day simple moving average is $32.15 and its 200-day simple moving average is $29.92.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new stake in shares of Genmab A/S in the third quarter worth approximately $12,972,000. JPMorgan Chase & Co. lifted its holdings in Genmab A/S by 17.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after purchasing an additional 135,814 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Genmab A/S by 24.1% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock valued at $9,687,000 after purchasing an additional 61,311 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares during the last quarter. Finally, Eagle Global Advisors LLC grew its holdings in shares of Genmab A/S by 16.3% during the third quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock worth $7,498,000 after buying an additional 34,175 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS view and bumped the price target to $40, increasing quarterly estimates for Q2–Q4 even as it trimmed Q1. The firm maintains a “Buy” rating, which likely helped lift the stock. HC Wainwright Increases Genmab A/S (NASDAQ:GMAB) Price Target to $40.00
• Positive Sentiment: Reported full-year revenue strength: Genmab posted ~19% revenue growth to about $3.7B in 2025, driven by proprietary medicine sales — a revenue beat/trajectory that supports higher earnings forecasts and investor confidence. Genmab (GMAB) reports 19% revenue growth to $3.7B in 2025 driven by proprietary medicine sales
• Neutral Sentiment: Jefferies initiated coverage on GMAB (coverage starts attention and can add liquidity); the initiation itself is noteworthy but the direction impact depends on the published rating/details. Jefferies Financial Group Initiates Coverage on Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Disclosure of transactions by managerial employees and closely associated persons was filed (routine regulatory reporting). Without details on buys vs. sells, this is primarily informational. Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
• Neutral Sentiment: Analyst roundup and commentary (Benzinga piece) summarizes multiple analyst views — useful context but no single catalyst. 3GMAB : A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts
• Neutral Sentiment: Short interest data in the feed appears anomalous (shows zero shares/ratio) and is not a reliable signal for current positioning.
• Negative Sentiment: Recent quarterly results included a sizeable EPS miss (reported $0.05 vs. consensus ~$0.46) despite revenue roughly in line — that miss is a primary reason the stock had pressure earlier and still weighs on near-term sentiment.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.